PVT 4206
Alternative Names: PVT-4206Latest Information Update: 25 Aug 2023
Price :
$50 *
At a glance
- Originator Proteovant Therapeutics
- Class Antineoplastics
- Mechanism of Action Estrogen receptor antagonists; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 14 Aug 2023 Proteovant Therapeutics has been acquired by SK biopharmaceuticals
- 22 Dec 2022 Preclinical trials in Breast cancer in USA (unspecified route) (Proteovant Therapeutics pipeline, December 2022)